Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ICMT | O60725 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994850 | 0.84 | ICMT (0.46) | MEN1KMT2AIDO1ALDH1A1L3MBTL1 | |
| SCHEMBL1994671 | 0.83 | F2 (0.48) | MEN1KMT2AIDO1ALDH1A1L3MBTL1 | |
| SCHEMBL30979650 | 0.79 | ALDH1A1 (0.55) | KMT2AALDH1A1 | |
| SCHEMBL13348961 | 0.78 | IDO1 (0.58) | MEN1KMT2AIDO1ALDH1A1L3MBTL1 | |
| SCHEMBL1992845 | 0.77 | CHRM2 (0.48) | IDO1F2PRSS1 | |
| SCHEMBL28780669 | 0.74 | SLC6A4 (0.75) | SLC6A4ALDH1A1GBA1HTR4 | |
| SCHEMBL7454904 | 0.73 | GBA1 (0.49) | SLC6A4GBA1 | |
| SCHEMBL29982985 | 0.72 | ALDH1A1 (0.65) | MEN1KMT2AIDO1ALDH1A1L3MBTL1 | |
| SCHEMBL5726304 | 0.71 | HTR6 (0.72) | — | |
| SCHEMBL28512724 | 0.70 | IDO1 (0.60) | MEN1KMT2AIDO1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | MEN1 427/4885KMT2A 3648/4885IDO1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.